Apollomics, Inc.
NASDAQ Capital Market•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Dr. Guo-Liang Yu Ph.D.
- Full Time Employees
- 13
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 989 East Hillsdale Blvd Foster City CA United States of America 94404
- IPO Date
- Nov 26, 2021
- CIK
- 0001944885
- Website
- apollomicsinc.com
- Similar Companies
- Business
- Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.
Company News
Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress
Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib
Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement
Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress
Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial
Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement
Apollomics Announces Updated Strategic Focus and Leadership Team Changes
Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene
Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer
Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Apollomics to Participate in a Fireside Chat at the B. Riley Securities' 2024 Virtual Oncology Conference
Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
Apollomics to Present at the 2024 Biotech Showcase
Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)